Boehringer Ingelheim Pharmaceuticals expands drug discovery alliance with Graffinity
Graffinity Pharmaceuticals GmbH announced that its partner Boehringer Ingelheim Pharmaceuticals, Inc. has chosen to exercise options in its original agreement with Graffinity that will significantly increase the number of targets screened by Graffinity as part of this global alliance. Under the terms of the agreement, Graffinity will receive additional technology access fees for the generation of multiple novel small molecule hit series against a variety of drug targets from different therapeutic areas.
Graffinity will apply its proprietary fragment based drug discovery technology and drug fragment chemical microarrays to identify small molecule hit structures focusing on compounds with novel modes of action. Financial details of the transaction were not disclosed.
Other news from the department business & finance
